Weight Loss Drug May Slow Aging by 9%, Study Finds

A drug millions already take for weight loss might do something remarkable: slow down how fast our cells age.

Researchers at UC San Diego found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging by 9% in a rigorous clinical trial. The study tracked 108 adults over 32 weeks and measured aging through "epigenetic clocks," which detect chemical markers on DNA that reveal how fast cells are aging.

Half the participants received weekly semaglutide injections while the other half got placebos. The difference showed up across multiple measures of aging linked to heart, brain, kidney, liver and metabolic health.

The drug significantly slowed biological processes tied to disease risk and mortality. It also reduced inflammation and metabolic stress, both major drivers of accelerated aging.

"We are not saying that semaglutide reverses aging or makes people younger," said lead researcher Dr. Michael Corley. "What we are seeing is a signal that it may slow some of the biological processes associated with aging."

A companion pilot study found even more encouraging results. After 24 weeks of treatment, 42% of participants showed slower biological aging rates. Nearly half showed increased telomere length, protective caps on chromosomes that typically shrink as we age. Those same participants walked faster after treatment, suggesting better physical function.

The studies focused on people with HIV, who often experience faster aging even with good medical care. But the findings could apply more broadly since the same aging processes happen in everyone.

Why This Inspires

This research opens doors scientists have been trying to unlock for decades. A medication already approved and widely available might help slow aging itself, not just treat individual diseases.

The potential reaches beyond any single health condition. If GLP-1 drugs genuinely slow biological aging, they could help prevent multiple age-related diseases at once rather than treating them one by one.

UC San Diego's Stein Institute for Research on Aging plans to create personalized "aging dashboards" that track biological markers. Doctors could use these tools to design treatments targeting the root mechanisms of aging.

Larger trials will determine how long the effects last and which patients benefit most. Future research will also test whether combining GLP-1 drugs with healthy lifestyle choices like exercise and good sleep creates even stronger results.

The takeaway feels quietly revolutionary: a tool to slow aging might already exist in medicine cabinets across the country.